An Incisive, In-depth Analysis on the Liquid Biopsy Market
This study offers a comprehensive, 360 degree analysis on the Liquid Biopsy market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Liquid Biopsy market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.
Key Factors Shaping the Liquid Biopsy Market
Diagnosis Accuracy and Higher Adoption Rate in Cancer Research
The advancements in noninvasive technology of liquid biopsy diagnosis, which in turn reduce false positive and negative results in cancer detection is a key factor expected to propel the growth of the global Liquid Biopsy Market. Increasing demand for technically advanced liquid biopsy product, in various cancers, such as breast cancer, prostate cancer, lung cancer, colon cancer and other cancer diseases, for improved and accurate diagnosis is anticipated to drive the growth of Liquid Biopsy Market over the forecast period. Noninvasive diagnosis methodology, minute biospecimens requirement and sophisticated procedures gaining the higher preference to liquid biopsy by the physicians over other conventional biopsy procedures. This increasing adoption in hospitals, diagnostic laboratories and research laboratories is expected to boost the growth of the future Liquid Biopsy Market. Extensive clinical research and R & D funding from government and industry is expected to propel the demand for liquid biopsy.
Increasing Anti-cancer Drug R & D Activities by Biotechnology and Biopharmaceutical Industry
There is an ever increasing demand for liquid biopsy from end users, such as hospitals, diagnostics centers and research institutes in the developed regions due to increasing incidences of various cancer diseases and high urge of early drug research and development. In the past decade, research and development activities for anti-cancer therapeutic products have reached an intense level. Various government and cancer institutes have allocated budgetary funds and grants for research and development activities to develop novel and cost effective anti-cancer drugs which will ultimately lead to an increased demand of accurate and rapid biopsy technique like liquid biopsy during clinical research and development activities. For Instance, according to the National Institute of Health (NIH), the federal government of U.S. allocated US$ 6.44 billion to National Cancer Institute (NCI) in 2020 fiscal year budget for cancer research and development in medical, technological and scientific development. Such rise in research funding will drive the growth of the Liquid Biopsy Market.
Increasing Strategic Collaborations among Industry Players and End Users
Strategic collaborations among liquid biopsy product manufacturer and end user, such as hospitals, diagnostics centers, cancer institute, and academic institutes are anticipated to drive growth of the Liquid Biopsy Market over forecast period in emerging regions such as Latin America and Southeast Asia. Collaboration activities, such as industry research funding, and product development agreements are preferred by industry players to strengthen their product portfolio and proprietary technologies dedicated to rapid diagnosis of variety of cancer diseases.
Liquid Biopsy Market Structure Analysis
- The global Liquid Biopsy Market is consolidated with over 65% market share occupied by tier I industry players.
- Tier I companies include F. Hoffmann-La Roche Ltd., Janssen Global Services, LLC, Biocept Inc., and Trovagene, Inc and others players.
- Most manufacturers are focused on scientific advancements in the global diagnostic healthcare sector by undertaking R&D initiatives to expand its product portfolio.
FREQUENTLY ASKED QUESTIONS ABOUT THE LIQUID BIOPSY MARKET
Why liquid biopsy market is expected to evidence double digit growth rate in the future?
Minimally-invasiveness, and rapid diagnosis with high accuracy and precision are the key factors expected to increase adoption of liquid biopsy among the end-users.
Which biomarkers type is expected to lead the liquid biopsy market?
Circulating Tumour Cells (CTCs) biomarkers are expected to hold majority share in the liquid biopsy market owing to expanded clinical applications which include prediction of cancer prognosis; selection and monitoring of therapeutic treatment; and drug targeted therapy.
Which type of disease holds the high market potential?
Lung cancer is a dominating disease area in the current liquid biopsy market owing to large patient base and capability of liquid biopsy to perform diagnosis with minimal sample.
What is the competitive nature of the current liquid biopsy market?
The liquid biopsy market is highly consolidated market with leading diagnostic, biotechnology and biopharmaceutical industry players.
Which region will lead the global sales of liquid biopsy market?
North America is currently dominating region in the global liquid biopsy market and expected to remain at the leading position in the future
This report by Future Market Insights (FMI) examines the ‘Liquid Biopsy Market’ for the period 2016–2026. The primary objective of the report is to offer updates and information related to market opportunities in the global liquid biopsy market.
The global liquid biopsy market report begins by defining liquid biopsy and various types of markers used in liquid biopsy. It is followed by an overview of market dynamics of the global liquid biopsy market, which includes FMI’s analysis of key trends, drivers, restraints and opportunities, and reimbursement scenario that is influencing the growth of the liquid biopsy market. It also includes an insight into case-studies and product pipeline. Impact analysis of key growth drivers and restraints based on a weighted average model have been included in the global liquid biopsy market report after detailed analysis of individual regions to better equip readers with meaningful insights on ongoing developments in the oncology market.
The primary factors fuelling demand for liquid biopsy diagnostic tests are growing incidences of lung, gastrointestinal and breast cancer. Other factors driving demand for liquid biopsy tests are increasing inclination of oncologists and physician to opt for non-invasive diagnostic procedures, reluctance of the patients to go painful biopsies and increase in the demand of personalized medicine. Whereas increasing number of test launches and entry of regional players also drives the market for liquid biopsy tests. However, a primary factor hampering growth of the liquid biopsy market is its penetration owing lower awareness of blood tests to detect cancer.
Based on market type, the market has been segmented into circulating tumour cells (CTCs), Circulating tumour Nucleic Acids (ctNA) and exosomes. A detailed analysis has been provided for these segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity and BPS analysis.
Based on sample type, the market has been segmented into blood, urine and others (plasma, saliva, CSF). Our analysis predicts that biopsies through blood samples would increase at a very fast pace, increasing the number of blood diagnostic test to detect cancer is expected to contribute significantly to increasing demand for liquid biopsies the forecast period.
Based on the disease indication the liquid biopsy market has been segmented into lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, colorectal cancer, leukemia and others. Lung cancer is expected to expand at a higher CAGR, due to increasing prevalence of lung cancer over the forecast period. Further, based on end-user segmentation, the market is segmented into hospitals, cancer institutes, academic institutes and diagnostic centres. Increasing commercialization of liquid biopsy test is expected to increase the revenue generation of liquid biopsies from hospitals and diagnostic centres surgery. This trend is expected to be particularly prominent in countries where access to healthcare services is increasing especially in APEJ
The next section of the report highlights liquid biopsy market by region and provides market outlook for 2016–2026. The report also discusses key regional trends contributing to the revenue growth of the liquid biopsy tests worldwide, as well as analyses the impact of drivers and restraints in each region. Key regions assessed in this report include North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan and Middle East & Africa (MEA).
The above sections—by marker type, sample type, disease indication, end users and region—evaluate the present scenario and growth prospects of the liquid biopsy tests market for 2016–2026. We have considered 2015 as the base year and provided data for the forecast period, i.e., 2016–2026.
To ascertain liquid biopsy tests market size, we have also considered revenue generated by companies in liquid biopsy market space. The forecast presented here assesses the total revenue by value across the liquid biopsy market. In order to offer an accurate forecast, we started by sizing up the current market, which forms the basis of how the liquid biopsy market is expected to develop in the future. Given the characteristics of the market, we triangulated the outcome of three different types of analysis based on supply side, downstream industry demand, and the economic envelope.
In addition, it is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyse it based on key parameters such as year-on-year (Y-o-Y) growth rates to understand the predictability of the market, and to identify the right opportunities across the global liquid biopsy market.
The liquid biopsy market segments in terms of marker type, sample type, disease indication, end user, and regions. These segments are analysed in terms of Basis Point Share (BPS) to understand individual segment’s relative contributions to market growth. This detailed level of information is important for identifying various key trends in the liquid biopsy market.
Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective, in the global liquid biopsy market.
To understand key growth segments in terms of growth and adoption for liquid biopsy tests globally, Future Market Insights developed the liquid biopsy market ‘Attractiveness Index’. The resulting index is expected to help providers identify real market opportunities in the overall oncology market.
In the final section of the report on the global liquid biopsy market, ‘Competitive Landscape’ is included to provide report audiences with a dashboard view, based on categories of test developers in the liquid biopsy market space and key differentiators. Key categories of providers covered in the report are companies developing liquid biopsy tests. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the liquid biopsy value chain and the potential players for the same. Report audiences can gain segment-specific company insights to identify and evaluate key competitors based on in-depth assessment of capabilities and successes in liquid biopsy marketplace.
Detailed profiles of the liquid biopsy tests developing companies are also included in the scope of the report to evaluate their long- and short-term strategies, key offerings, SWOT analysis, and recent developments in the global liquid biopsy market.
Key competitors covered in terms of liquid biopsy test developing companies BIOCEPT, INC., Qiagen N.V., Trovagene, Inc., Janssen Global Services, LLC, MDxHealth SA, Natera, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, Sysmex Corporation.
Key Segments Covered
- By Marker Type
- CTCs (Circulating tumour Cells)
- ctNA (Circulating tumour Nucleic Acids)
- By Sample Type
- Others (Plasma, Saliva, CSF)
- By Disease Indication
- Lung Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- By End-User
- Cancer Institutes
- Academic Institutes
- Diagnostic Centers
Key Regions/Countries Covered
- North America
- Latin America
- Rest of Latin America
- Western Europe
- Rest of Western Europe
- Eastern Europe
- Rest of Eastern Europe
- Asia Pacific Ex. Japan (APEJ)
- Australia and New Zealand
- Rest of APAC
- Middle East & Africa
- South Africa
- Rest of MEA
- BIOCEPT, INC.
- Qiagen N.V.
- Trovagene, Inc.
- Janssen Global Services, LLC
- MDxHealth SA
- Natera, Inc.
- Hoffmann-La Roche Ltd.
- Silicon Biosystems
- Pathway Genomics Corporation
- Sysmex Corporation